aTyr Pharma (ATYR) Proxy filing summary

Executive summary

• Annual Meeting scheduled for May 11, 2026, at 9:00 a.m. Pacific Time at company headquarters.

• Proxy materials, annual report, and meeting directions are available online, with options to request paper or email copies.

• Stockholders are invited to attend and participate in voting on key proposals.

Voting matters and shareholder proposals

• Election of three Class II directors to serve until the 2029 annual meeting or until successors are elected.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote to approve executive compensation.

• Approval of an amendment to the 2015 Stock Option and Incentive Plan.

• Approval of an amendment to increase authorized common stock from 170,000,000 to 340,000,000 shares.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and proposals.

• Nominees for Class II directors: Eric Benevich, Timothy P. Coughlin, Jane A. Gross, Ph.D.